CAR-T talks: Continuous improvements in the commercial manufacturing of tisagenlecleucel in Europe
The autologous CD19-directed CAR-T cell therapy tisagenlecleucel (Kymriah ® ) has been approved by the European Medicines Agency (EMA) for the treatment of children and young adults (aged ≤25 years) with relapsed/refractory (r/r) B...